Nippon Shinyaku and Elixirgen partner on Duchenne drug

Japan’s Nippon Shinyaku has entered into an option agreement with US-based Elixirgen Therapeutics, giving the Japanese company the right to obtain exclusive worldwide rights to develop and commercialize EXG-7001, an experimental drug for Duchenne muscular dystrophy. The deal was facilitated by the NS Pharma Innovation Research Partnering team in Cambridge, Massachusetts.

An option agreement for a promising experimental therapy

Under the terms of the agreement, Nippon Shinyaku may exercise its option to license EXG-7001 after certain conditions are met. If it does, and after securing regulatory approval in the United States, NS Pharma — the drug development subsidiary of the Japanese firm — intends to commercialize the treatment.

EXG-7001 is an investigational, locally administered mRNA-based therapeutic that expresses full-length human dystrophin protein.

That’s a key detail: it delivers the complete protein, not a shortened version. The drug is designed to work regardless of the patient’s specific genetic mutation, which could make it applicable to a broader range of people with DMD.

“Collaboration is essential in furthering scientific innovation, and we are proud to partner with Elixirgen to expand treatment options for the Duchenne community,” said NS Pharma President Yukiteru Sugiyama.

What makes EXG-7001 different

Duchenne muscular dystrophy is a severe, progressive genetic disorder that causes muscle weakness due to the absence or dysfunction of dystrophin, a protein that helps keep muscle cells intact. Most current treatments focus on managing symptoms or targeting specific mutations. The therapy aims to suppress local muscle dysfunction by expressing the full-length dystrophin protein directly within muscle cells, where it’s deficient.

The therapy is still in preclinical development. Elixirgen is currently preparing for clinical trials in the United States, though no timeline has been given. The mRNA approach — the same technology used in some COVID-19 vaccines — has drawn attention for its potential to deliver large proteins, but it also faces challenges around delivery, durability, and immune response that will need to be worked out in human studies.

For now, the partnership gives the firm a foothold in a competitive space.

Other companies are pursuing gene therapies, exon-skipping drugs, and steroid alternatives for DMD. The therapy’s claim to fame is its ability to produce the full-length dystrophin protein, which no currently approved therapy does. If it works, it could address the underlying protein deficiency in a way that mutation-specific drugs cannot.

But the preclinical stage is early.

The option agreement allows the firm to evaluate clinical data before committing fully.

The company’s decision to move forward will depend on results from the upcoming trials — and on whether the therapy can safely deliver the full-length protein to enough muscle tissue to make a difference in a disease that affects about one in every 3,500 male births worldwide.